Status and phase
Conditions
Treatments
About
SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death.
This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically-confirmed stage II, III and IV squamous cell carcinoma of the head and neck.
Patient's tumor is fully resectable and does not require radiotherapy to the entire buccal mucosa or patients who are to be treated with definitive radiation therapy as long as adequate (>2cm^3) of tissue can be obtained post-therapy with SCH66336.
ECOG Performance Status of </= 2
Laboratory values (performed within 14 days prior to administration of SCH 66336):
Able to provide written informed consent.
Negative pregnancy test (female patients of childbearing potential only), after signing informed consent and prior to registration.
Patients may have received prior investigational therapy but at least 4 weeks must have elapsed with recovery from all toxicities.
No more than two prior chemotherapy regimens for systemic disease.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal